Biohaven to be Acquired by Pfizer for $11.6 Billion

Posted by ISPE Boston
On May 13, 2022

New Haven biotech Biohaven has agreed to be acquired by Pfizer in a proposed transaction valued at $11.6 billion. The acquisition includes Biohaven’s calcitonin gene-related peptide (CGRP) migraine therapy programs. These include rimegepant (approved in the U.S. and the EU under the trade names Nurtec and Vydura, respectively), and zavegepant, which is on track for a […]

AstraZeneca to Open New Site in Kendall Square

Posted by ISPE Boston
On May 13, 2022

AstraZeneca plans to open a new site at the heart of the Cambridge life sciences and innovation hub. The new site will be a strategic R&D center for AstraZeneca, as well as corporate headquarters for Alexion, which was acquired by AstraZeneca in July 2021. The site will consolidate approximately 1,500 R&D, commercial and corporate professionals […]

WIP’s Splendid Succulent Plant Party!

Posted by ISPE Boston
On May 12, 2022

ISPE Boston’s Women in Pharma Committee really knows how to throw a party! And not just any old party – a DIY succulent plant party! After a long awaited time, this event finally happened last night at Craft Food Halls at CityPoint in Waltham. With a 99% attendance rate compared with registrations, this event was […]

ISPE Boston Past Presidents Social Outing

Posted by ISPE Boston
On May 12, 2022

Last night, ISPE Boston’s Past Presidents got together for a lovely social evening of networking along with some delicious food and beverages. Everyone was very excited to socialize and are planning to do this event again soon. With all the mask requirements and social distancing guidelines in place for the past few years, it was […]

We Need Your Feedback – 30 Second Blog Survey!

Posted by ISPE Boston
On May 10, 2022

Please take this brief 3 question survey to provide feedback on the ISPE Boston blog! The Communications Committee is working on enhancing our blog content and would love to hear from YOU! Link to survey: https://lp.constantcontactpages.com/sv/qEfP1BT/blogsurvey

Biogen Abandons Aduhelm, Searches for New CEO

Posted by ISPE Boston
On May 5, 2022

In reporting its first quarter 2022 results, Biogen announced that it has begun a search for a new CEO. Michel Vounatsos, who has held the position since 2017, will continue to serve as CEO and on the Board of Directors until his successor is appointed. The company also announced it will “substantially eliminate its commercial […]

Vertex Stem Cell Study Suffers Setback

Posted by ISPE Boston
On May 5, 2022

Vertex has announced that its VX-880 Phase 1/2 study has been placed on clinical hold in the U.S. by the FDA. VX-880 is an investigational stem cell-derived, pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). According to Vertex, the FDA took this action due to its determination that there is “insufficient […]

Apertura Gene Therapy Launches with $67M

Posted by ISPE Boston
On May 5, 2022

Apertura Gene Therapy has launched with a Series A financing of up to $67M from Deerfield Management Company to develop genetic medicines. Deerfield Management has also committed additional operational support. Apertura is based at the Cure, Deerfield’s innovation campus in New York City. Apertura is founded on a pair of platform technologies developed in the […]

First ISPE Boston Podcast Club a Success!

Posted by Jesse McLaughlin
On May 3, 2022

Last Wednesday we had our very first “Podcast Club” meeting. No, we didn’t just sit around with our earbuds in listening to our favorite podcasts…and I don’t think anyone was wearing a t-shirt of their favorite podcast host… We did, however, have a great discussion about the future of the Pharma industry! Kind of like […]

Chapter Member Anniversaries: May 2022

Posted by ISPE Boston
On May 3, 2022

Please congratulate the following members celebrating milestone anniversaries in May 2022. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Beth Ann Billotto, Regeneron Pharmaceuticals Inc Karen Conte, Pfizer Timothy Crowley, Sentrol, Inc. John Evers, Lantheus Medical Imaging Joshua Froimson, AbbVie Bioresearch Center Doyle Johnson Jr., IPS Marina […]

Page 35 of 118«‹33 343536 37 ›»